While drug companies enjoy high margins and long product lives, device companies have an edge in faster-to-market approvals and lower risk. The best device would marry the two, creating products that are easy to get to market and have high reward. Device-oriented drug delivery systems are one example.
You may also be interested in...
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
Likelihood of webcast-only advisory committee meetings may depend on the extent of the coronavirus outbreak, Office of New Drugs Director Peter Stein tells the Pink Sheet in an interview.
'We've got be sure that companies can continue to get ingredients for their products," says CRN CEO Steve Mister, Concern supplies from India, which is a week into a a three-week nationwide lockdown, and other potential supply chain problems were noted by CRN members in a survey it conducted to help USDA gauge global food and nutrition ingredient supply chains during the pandemic.